Examkin

Question

Difficulty: Very hardHematology and Oncology

An emergency department physician evaluates a 71-year-old man for progressively blurred vision, recurrent severe epistaxis, and confusion over the past two weeks. On physical examination, the patient appears lethargic. Fundoscopy reveals tortuous, engorged retinal veins with a classic 'sausage-link' appearance alongside bilateral retinal hemorrhages. Initial laboratory studies show:

Laboratory ParameterValue
Hemoglobin9.2 g/dL
Total serum protein10.8 g/dL
Albumin3.4 g/dL

Subsequent serum protein electrophoresis identifies a prominent monoclonal spike in the gamma-globulin region. His serum viscosity is markedly elevated at 5.8 centipoise (normal: 1.4-1.8).

Arrange the following steps in the most appropriate and safe chronological sequence for the management of this patient:

  1. 1Draw peripheral blood for immunofixation electrophoresis and quantitative immunoglobulins
  2. 2Perform emergent therapeutic plasmapheresis
  3. 3Obtain a bone marrow aspiration and biopsy
  4. 4Initiate systemic chemoimmunotherapy (e.g., rituximab and bendamustine)

Answer

The correct sequence is to first draw diagnostic blood tests, followed by emergent therapeutic plasmapheresis to stabilize the patient, then perform a bone marrow biopsy for definitive tissue diagnosis, and finally initiate systemic chemoimmunotherapy.
The correct sequence prioritizes securing diagnostic evidence before altering it, immediately managing the life-threatening emergency, confirming the underlying pathology safely, and finally treating the root cause. First, blood must be drawn for immunofixation to capture accurate baseline immunoglobulin levels. Second, emergent plasmapheresis is performed to rapidly reverse the life-threatening hyperviscosity syndrome. Third, after the patient is stabilized and bleeding risk is reduced, an invasive bone marrow biopsy is safely obtained for definitive tissue diagnosis. Finally, systemic chemoimmunotherapy is initiated to treat the underlying Waldenström macroglobulinemia, ensuring this occurs post-plasmapheresis to avoid a dangerous rituximab-induced IgM flare.

Step-by-Step Solution

1
Draw peripheral blood for immunofixation electrophoresis and quantitative immunoglobulins
Establishes baseline immunoglobulin levels and characterizes the monoclonal protein as IgM.
Must be performed prior to plasma exchange; otherwise, the therapeutic removal of immunoglobulins will artificially lower the diagnostic levels and obscure the true nature of the gammopathy.
2
Perform emergent therapeutic plasmapheresis
Rapidly clears high-molecular-weight IgM pentamers from the intravascular space, decreasing serum viscosity.
Hyperviscosity syndrome with end-organ damage (confusion, retinal hemorrhages) is an emergency requiring immediate mechanical removal of the offending protein to prevent irreversible ischemic strokes or coma.
3
Obtain a bone marrow aspiration and biopsy
Provides tissue to definitively identify a lymphoplasmacytic cellular infiltrate.
An invasive biopsy is safely performed after the patient is stabilized and hyperviscosity-induced platelet dysfunction is corrected. It is required for the definitive diagnosis of Waldenström macroglobulinemia.
4
Initiate systemic chemoimmunotherapy (e.g., rituximab and bendamustine)
Targets the underlying malignant clonal B-cells to provide long-term disease control.
Definitive therapy is started after pathologic confirmation. Importantly, administering rituximab prior to plasmapheresis is contraindicated here, as it can trigger a paradoxical 'IgM flare' that sharply increases viscosity.

Key Concept

Waldenström Macroglobulinemia and Hyperviscosity Syndrome Management
Estimated Time:2m 0s
Rate this question

Topics

Hematology and Oncology

More questions from this topic